Skip to main content
. 2007 Jan 31;104(6):1931–1936. doi: 10.1073/pnas.0610593104

Fig. 1.

Fig. 1.

Schematic representation of the rescue construct. (A) Mecp2e2 cDNA (white box), CAGGS promoter (dark gray box), stop cassette (light gray box), LoxP sites (black boxes). The construct was targeted to the Col1a1 locus. Expression of Cre will loop out the stop cassette, allowing the expression of MeCP2e2. (B) Characteristics of the Cre lines used. (C) Western blot analysis of tissue from WT (lanes 1), transgenic (CAGGS LSL Mecp2; Mecp2 −/y, lanes 2), and Mecp2 −/y (KO) mice (lane 3). No MeCP2 signal was detected in brain, lung, and spleen of null animals containing the CAGGS LSL Mecp2 transgene. Anti-GAPDH was used as loading control. (D) Western blot of total brain extracts of 6-week-old animals. Lane 1, endogenous MeCP2 in WT brain. The higher, stronger band corresponds to MeCP2e1, and the lower, fainter band corresponds to the MeCP2e2. Lane 2: Mecp2 −/y (KO); CAGGS LSL Mecp2. Lanes 3 and 4: Nestin and Tau Cre rescued animals, respectively. Lanes 5 and 6: C93 and C159 rescued mice. (E and F) Western blot analysis of CAGGS MeCP2 expression in cortex (Co), hippocampus (Hi), and cerebellum (Ce). Tau and Nestin Cre activate the transgene in all areas (E, lanes 4–9), whereas C93 and C159 activate Mecp2 in cortex and hippocampus (F, lanes 4, 5, 7, and 8) but not in cerebellum (F, lanes 6 and 9). E and F, lanes 1–3 show endogenous MeCP2.